--- title: "13:22 ETISPE Announces its 2026 ISPE Aseptic Conference Keynote Speakers" type: "News" locale: "en" url: "https://longbridge.com/en/news/275498993.md" description: "The International Society for Pharmaceutical Engineering (ISPE) has announced the keynote speakers for the 2026 ISPE Aseptic Conference, scheduled for March 23-24, 2026, in Washington, D.C., and virtually. The conference will feature industry experts discussing aseptic processing and sterile manufacturing, with tracks covering various topics such as Airflow Testing and Facility Design. Keynote speakers include Brooke Higgins from Eliquent Life Sciences, Vivianne Arencibia from Lonza AG, and Rick Friedman from the FDA. The event aims to address urgent industry challenges and foster collaboration among professionals in the pharmaceutical sector." datetime: "2026-02-10T18:23:56.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/275498993.md) - [en](https://longbridge.com/en/news/275498993.md) - [zh-HK](https://longbridge.com/zh-HK/news/275498993.md) --- > Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/275498993.md) | [繁體中文](https://longbridge.com/zh-HK/news/275498993.md) # 13:22 ETISPE Announces its 2026 ISPE Aseptic Conference Keynote Speakers _The 2026 ISPE Aseptic Conference will take place 23–24 March 2026 in Washington, D.C., United States, and virtually._ , /PRNewswire/ -- The International Society for Pharmaceutical Engineering (ISPE) has announced its keynote speakers for the 2026 ISPE Aseptic Conference, set for Monday, 23 March, through Tuesday, 24 March, in Washington, D.C., United States, and virtually. Continue Reading The 2026 ISPE Aseptic Conference will feature insights from industry experts and regulators across various technical tracks. "The speakers at the 2026 ISPE Aseptic Conference are driving the next era of aseptic processing and sterile manufacturing," said Keith Weseli, Advisor – Program Manager, Eli Lilly & Company, and 2026 ISPE Aseptic Conference Chair. "With a dynamic agenda, world-class expertise, and unparalleled opportunities for collaboration, the 2026 conference in Washington, D.C. will be the year's most influential forum for professionals across the pharmaceutical, biotechnology, and advanced therapy sectors. We've designed this program to tackle the industry's most urgent challenges and emerging opportunities head on." ISPE has announced keynote speakers for the event, which include: - Brooke Higgins, Senior Vice President for Regulatory Compliance, Eliquent Life Sciences - Vivianne Arencibia, Head of Quality Auditing and Risk Management, Lonza AG - Rick Friedman, Deputy Director, Office of Manufacturing Quality, US Food and Drug Administration/Center for Drug Evaluation and Research This year's conference comprises technical tracks spanning topics such as Airflow Testing, Annex 1 Case Studies, Advanced Therapy Medicinal Products, Component Quality, Facility Design, Isolator Design, Lyophilization, Radiopharmaceuticals and High Potent Compounds, and Sterile Processing. Each track includes curated educational sessions featuring data-driven insights, case studies, and practical real-world examples. Learn more and register for the 2026 ISPE Aseptic Conference today: ISPE.org/26Aseptic. **About ISPE **The International Society for Pharmaceutical Engineering (ISPE) is a global nonprofit association serving its members through leading scientific, technical, and regulatory advancement across the entire pharmaceutical lifecycle. The 25,000+ members of ISPE provide solutions to complex pharmaceutical industry challenges through innovation, member and workforce development, and technical, regulatory, and compliance collaborations in more than 120 countries worldwide. Founded in 1980, ISPE has its worldwide headquarters and training center in North Bethesda, Maryland, USA, and its operations center in Tampa, Florida, USA. For more information, visit ISPE.org. SOURCE ISPE ### Related Stocks - [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md) - [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md) - [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md) - [Lonza Group AG (LZAGY.US)](https://longbridge.com/en/quote/LZAGY.US.md) - [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md) - [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md) - [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md) - [Lonza Group AG (O6Z.SG)](https://longbridge.com/en/quote/O6Z.SG.md) - [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md) ## Related News & Research - [FDA approves Ascendis Pharma’s weekly Yuviwel for paediatric dwarfism](https://longbridge.com/en/news/277455732.md) - [Xeris Biopharma Q4 product revenue beats analyst expectations, driven by higher patient demand](https://longbridge.com/en/news/277460502.md) - [Veeva Systems Q4 revenue eases past estimates](https://longbridge.com/en/news/277834275.md) - [Rallybio to acquire Candid Therapeutics](https://longbridge.com/en/news/277617458.md) - [908 Devices Q4 revenue beats on FTIR product strength](https://longbridge.com/en/news/277617498.md)